CytomX CBO Jeffrey Landau to depart effective Feb 7, 2025

CytomX Therapeutics, Inc.

Jeffrey Landau, SVP, Chief Business Officer, and Head of Strategy, will leave the company on February 7, 2025.
Separation agreement provides economic payments consistent with existing severance and change of control agreement.
Separation includes a general release of claims against the company.
No replacement for Landau's role has been announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jeffrey Landau

Senior Vice President, Chief Business Officer, and Head of Strategy

CTMX · CytomX Therapeutics, Inc.

Effective: 2025-02-07
Filed: February 3, 2025, 6:59 PM ET

On January 30, 2025, Jeffrey Landau, Senior Vice President, Chief Business Officer, and Head of Strategy, of CytomX Therapeutics, Inc. (the “Company”) and the Company agreed that Mr. Landau’s employment by the Company would terminate, effective February 7, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey Landau was terminated as Senior Vice President, Chief Business Officer, and Head of Strategy at CytomX Therapeutics, Inc..

Action: terminated
Role: Senior Vice President, Chief Business Officer, and Head of Strategy

Exact text from the filing

On January 30, 2025, Jeffrey Landau, Senior Vice President, Chief Business Officer, and Head of Strategy, of CytomX Therapeutics, Inc. (the “Company”) and the Company agreed that Mr. Landau’s employment by the Company would terminate, effective February 7, 2025.

View on SEC.gov

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-019257

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.